Singapore-  South San Francisco, CA-based Tricida (TCDA) has filed a preliminary prospectus for a $150M IPO.

The company says its goal is to slow the progression of chronic kidney disease (CKD) via the treatment of metabolic acidosis (MA). Lead candidate is Phase 3-stage TRC101, a non-absorbed polymer designed to treated MA by binding to and removing acid from the GI tract. A U.S. marketing application is on tap for H2 2019.